Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aura Biosciences, Inc.AURA · Entity 5142 | Director | June 11, 2026 | June 15, 2026 |
| TAKEDA PHARMACEUTICAL CO LTDTAK · Entity 2662 | President, OBU | August 10, 2026 | August 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aura Biosciences, Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,000 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 15,000 · Balance 36,000 F1: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.21 · Expires 2036-06-11 | Direct | 30,000 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Grant · Acquired 30,000 · Balance 30,000 F2: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date.
F2: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date.
TAKEDA PHARMACEUTICAL CO LTD
Report date August 10, 2026 · Filed August 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 252,010 |
Reported balance
After 2026-08-10 transaction · row 1
1 source rowRow 1 · 2026-08-10 · Sale · Disposed 50,012 · Balance 252,010 F1: Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Fusion Pharmaceuticals Inc.
Report date June 04, 2024 · Filed June 04, 2024
Section 16 reporting ended · disclosed 2024-06-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.16 | Direct | 0 |
Reported balance
After 2024-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-04 · Disposition to issuer · Disposed 34,000 · Balance 0 F1: Pursuant to the Arrangement Agreement, dated as of March 18, 2024 (the "Arrangement Agreement"), by and among the Issuer, AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden ("Parent") and 15863210 Canada Inc., a corporation formed under the Canada Business Corporations Act ("Purchaser"), Purchaser acquired all of the issued and outstanding common shares of the Issuer (collectively, the "Shares") effective as of 12:01 a.m. Toronto time on June 4, 2024 (the "Effective Time"). Following the Effective Time, each Share outstanding immediately prior to the Effective Time was assigned and transferred by the holder thereof to Purchaser in exchange for (i) US$21.00 in cash (the "Cash Consideration") plus (ii) one contingent value right (each, a "CVR") representing the contingent right to receive a cash payment equal to US$3.00, in each case subject to applicable tax withholdings and other source deductions. F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Arrangement Agreement, dated as of March 18, 2024 (the "Arrangement Agreement"), by and among the Issuer, AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden ("Parent") and 15863210 Canada Inc., a corporation formed under the Canada Business Corporations Act ("Purchaser"), Purchaser acquired all of the issued and outstanding common shares of the Issuer (collectively, the "Shares") effective as of 12:01 a.m. Toronto time on June 4, 2024 (the "Effective Time"). Following the Effective Time, each Share outstanding immediately prior to the Effective Time was assigned and transferred by the holder thereof to Purchaser in exchange for (i) US$21.00 in cash (the "Cash Consideration") plus (ii) one contingent value right (each, a "CVR") representing the contingent right to receive a cash payment equal to US$3.00, in each case subject to applicable tax withholdings and other source deductions.
F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2026 Filed Aug 13, 2026 01:45 UTC | TAKEDA PHARMACEUTICAL CO LTD TAK · Entity 2662 | SaleAmerican Depositary Shares | 50,012 | $17.10 | $855,205.20 |
DisclosureSEC source: 0001493152-26-037502 · ownership.xml · nonDerivative · entry 1 Bitetti Teresa Marie · CIK 0001977608 · President, OBU 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252,010 F1 · kind: Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:02 UTC | TAKEDA PHARMACEUTICAL CO LTD TAK · Entity 2662 | GrantAmerican Depositary Shares | 43,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001395064-26-000247 · wk-form4_1783375354.xml · nonDerivative · entry 1 Bitetti Teresa Marie · CIK 0001977608 · President, OBU 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 302,022 F1 · kind: Represents an award of restricted stock units (RSUs). Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest in three equal annual installments beginning on July 1, 2027. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:31 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $6.21 | $0.00 |
DisclosureSEC source: 0001193125-26-271171 · ownership.xml · derivative · entry 2 Bitetti Teresa Marie · CIK 0001977608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-06-11 F2 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:31 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-271171 · ownership.xml · nonDerivative · entry 1 Bitetti Teresa Marie · CIK 0001977608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. Read SEC document |
| April 27, 2026 Filed Apr 28, 2026 10:06 UTC | TAKEDA PHARMACEUTICAL CO LTD TAK · Entity 2662 | GrantAmerican Depositary Shares | 64,988 | $0.00 | $0.00 |
DisclosureSEC source: 0001395064-26-000132 · wk-form4_1777370765.xml · nonDerivative · entry 1 Bitetti Teresa Marie · CIK 0001977608 · President, OBU 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 258,136 F1 · kind: On July 1, 2023, the reporting person was granted an award of restricted stock units (RSUs), which vest in the form of American Depositary Shares based upon the achievement of the specified performance metrics, including core revenue, core operating profit, and important R&D milestones. On April 27, 2026, the Compensation Committee of the Board of Directors determined the number of RSUs to be awarded based on these performance metrics, which amount is reported above. F2 · balance_after: Includes 150,790 restricted stock units (RSUs). Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest on the following schedule: July 1, 2026 (105,044 shares), July 1, 2027 (30,564 shares) and July 1, 2028 (15,182 shares). Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 20:02 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 29,000 | $0.00 Strike: $5.86 | $0.00 |
DisclosureSEC source: 0000950170-25-049279 · ownership.xml · derivative · entry 2 Bitetti Teresa Marie · CIK 0001977608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,000 Underlying: Common Stock · 29,000 shares Expires 2035-03-31 F2 · derivative.exercise_date: The shares underlying this option vest in three substantially equal annual installments beginning on March 31, 2026, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 20:02 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 21,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-049279 · ownership.xml · nonDerivative · entry 1 Bitetti Teresa Marie · CIK 0001977608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,000 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in three substantially equal annual installments beginning on April 15, 2026, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| June 04, 2024 Filed Jun 4, 2024 17:35 UTC | Fusion Pharmaceuticals Inc. FUSN · Entity 11851 | Disposition to issuerStock Option (Right to Buy) · Derivative | 34,000 | Not disclosed Strike: $4.16 | Not disclosed |
DisclosureSEC source: 0000950170-24-068912 · ownership.xml · derivative · entry 1 Bitetti Teresa Marie · CIK 0001977608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,000 shares Expires not disclosed F1 · security: Pursuant to the Arrangement Agreement, dated as of March 18, 2024 (the "Arrangement Agreement"), by and among the Issuer, AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden ("Parent") and 15863210 Canada Inc., a corporation formed under the Canada Business Corporations Act ("Purchaser"), Purchaser acquired all of the issued and outstanding common shares of the Issuer (collectively, the "Shares") effective as of 12:01 a.m. Toronto time on June 4, 2024 (the "Effective Time"). Following the Effective Time, each Share outstanding immediately prior to the Effective Time was assigned and transferred by the holder thereof to Purchaser in exchange for (i) US$21.00 in cash (the "Cash Consideration") plus (ii) one contingent value right (each, a "CVR") representing the contingent right to receive a cash payment equal to US$3.00, in each case subject to applicable tax withholdings and other source deductions. F2 · price: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.exercise_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.expiration_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. Read SEC document |
| October 16, 2023 Filed Oct 16, 2023 16:59 UTC | Fusion Pharmaceuticals Inc. FUSN · Entity 11851 | GrantStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001209191-23-052878 · doc4.xml · derivative · entry 1 Bitetti Teresa Marie · CIK 0001977608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2033-10-16 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 36 substantially equal monthly installments starting on November 16, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.